Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Robert Allison

Physician Assistant Allentown, PA Physician Assistant

NPI 1164753810 CMS profile 11229392

1501 N Cedar Crest Blvd Ste 110, Allentown, PA 18104

Open in the dashboard

General payments

$6,209

391 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Allison of Allentown, PA is reported in the CMS Open Payments database as having received $6,209 across 391 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $598 26
2024 General $1,960 113
2023 General $1,375 83
2022 General $1,322 99
2021 General $955 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Allison
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Robert Allison were reported at $598. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Robert Allison Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $955 $132 $37–$438 $132
2022 $1,322 $155 $48–$522 $149
2023 $1,375 $167 $52–$557 $160
2024 $1,960 $178 $55–$600 $164
2025 $598 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,553 99 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,044 62 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $928 74 payments
  4. Janssen Biotech, Inc. $783 43 payments
  5. Ironwood Pharmaceuticals, Inc $291 21 payments
  6. Ferring Pharmaceuticals Inc. $274 14 payments
  7. Aimmune Therapeutics, Inc. $213 14 payments
  8. Braintree Laboratories, Inc. $203 14 payments
  9. Phathom Pharmaceuticals, Inc. $148 7 payments
  10. Nestle HealthCare Nutrition Inc. $132 10 payments
  11. Other $639 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,124 390 payments
  2. Education $85 1 payment
Products named General payments · program years 2021–2025
  1. XIFAXAN $928 74 payments
  2. ENTYVIO $786 43 payments
  3. LINZESS Gastroenterology $514 38 payments
  4. RINVOQ $457 24 payments
  5. STELARA $425 29 payments
  6. SKYRIZI $403 22 payments
  7. CREON $401 28 payments
  8. TREMFYA $358 14 payments
  9. ZENPEP $334 23 payments
  10. Linzess Gi $291 21 payments
  11. Other $2,362 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,842

Median for Physician Assistant: 241

Drug cost

$390,441

Median for Physician Assistant: $4,110

Branded share of claims

16.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 31 $99,903
Humira(Cf) Adalimumab Brand 14 $95,362
Linzess Linaclotide Brand 70 $66,199
Mesalamine Generic 78 $40,097
Dexlansoprazole Dr Dexlansoprazole Brand 50 $16,997
Pentasa Mesalamine Brand 15 $16,606
Pantoprazole Sodium Generic 702 $9,879
Trulance Plecanatide Brand 16 $8,838
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 36 $6,010
Ursodiol Generic 19 $4,701

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$66,588

Medicare's payments for the services billed

Medicare patients

670

Average age 73

Services billed

1,150

343 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 31%
Ischemic heart disease 26%
Chronic kidney disease 25%
Cancer 19%
Depression 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $299
$299 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $271
$271 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $112
  • AbbVie, Inc. $98
$209 70 —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $165
$165 — —
STELARA
  • Janssen Biotech, Inc. $163
$163 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

391 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record